The role of lipids in cardiovascular disease: Lessons from rare mutations and special populations

Clinical and Investigative Medicine

Volumn 19, Issue 3, 1996, Pages 161-170

  Hegele, Robert A ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

ATHEROGENESIS; CANADA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FAMILY; FEMALE; GENE MUTATION; HEALTH CARE DELIVERY; HEREDITY; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; MALE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MUTATION;

EID: 0029899326     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
2. Goldman L, Goldman PA, Williams LW et al: Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993; 72: 75D-79D
3. Davey-Smith G, Song F, Sheldon TA: Cholesterol lowering and mortality: the importance of considering the initial level of risk. BMJ 1993; 306: 1367-1373
4. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993; 362: 801-809
5. Marenberg ME, Risch N, Berman LF et al: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-1046
6. Davignon J, Roy M: Familial hypercholesterolemia in French Canadians: taking advantage of a "founder effect." Am J Cardiol 1993; 72: 6D-10D
7. Walden CC, Hegele RA: Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994; 120: 1026-1036
8. Mehrabian M, Lusis AJ: Genetic markers for studies of atherosclerosis and related risk factors. In Lusis AJ, Rotter JI, Sparkes RS (eds): Molecular Genetics of Coronary Artery Disease: Candidate Genes and Processes in Atherosclerosis, Monograph in Human Genetics series, Karger, Basel, Switzerland, 1992: 363-418
9. Sing CF, Haviland MB, Templeton AR et al: Alternative genetic strategies for predicting risk of atherosclerosis. Atherosclerosis 1994; 109: 333
10. Brown GB, Zhao X-Q, Sacco D et al: Lipid lowering and plaque regression. Circulation 1993; 87: 1781-1791
11. Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study. Lancet 1994; 344: 1383-1389
12. DeBakey ME: Patterns of atherosclerosis and rates of progression. Atherosclerosis 1978; 3: 1-56
13. Stary HC: Changes in the cells of atherosclerotic lesions as advanced lesions evolve in coronary arteries of children and young adults. In Glagov S, Newman WP, Schaffer SA (eds): Pathobiology of the Human Atherosclerotic Plaque, Springer, New York, 1990: 93-106
14. Hegele RA, Emi M, Wu LL et al: Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am J Cardiol 1989; 63: 109-112
15. Kern F Jr: Normal plasma cholesterol in an 88-year-old man who eats 25 eggs a day. N Engl J Med 1991; 324: 896-899
16. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 1994; 265: 2037-2048
17. Feldman DL, Hoff H, Gerrity RG: Immunohistochemical localization of apoprotein B in aortas from hyperlipemic swine: preferential accumulation in lesion-prone areas. Arch Pathol Lab Med 1984; 108: 817-822
18. Gerrity RG: The role of the monocyte in atherogenesis. 1. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981; 103: 181-190
19. Steinberg D, Parasarathy S, Carew TE et al: Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320: 915-924
20. Hawiger J: Adhesive interactions of the blood cells and the vascular wall. In Colman RW, Hirsch J, Marder VJ (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice, JB Lippincott, Philadelphia, 1994: 762-796
21. Constantinides P: Plaque ruptures, their genesis and their role in supraplaque thrombosis and atherogenesis. In Glagov S, Newman WP, Schaffer SA (eds): Pathobiology of the Human Atherosclerotic Plaque, Springer, New York, 1990: 393-411
22. Breslow JL: Familial disorders of high density lipoprotein metabolism. In Scriver CR, Beardet al, Sly WS et al (eds): The Metabolic Basis of Inherited Diseases, McGraw Hill, New York, 1989: 1251-1266
23. Assmann G, Schmitz G, Brewer HB Jr: Familial high density lipoprotein deficiency: Tangier disease. In Scriver CR, Beaudet al, Sly WS et al (eds): The Metabolic Basis of Inherited Diseases, McGraw Hill, New York, 1989: 1267-1282
24. Funke H, Assmann G: The lowdown on lipoprotein lipase. Nat Genet 1995; 10: 6-7
25. Johnson WJ, Mahlberg FH, Rothblat GH et al: Cholesterol transport between cells and high density lipoproteins. Biochim Biophys Acta 1991; 1085: 273-298
26. Rubin EM, Krauss RM, Spangler EA et al: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991; 353: 265-267
27. Schultz JR, Rubin EM: The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994; 5: 126-137
28. Li H, Reddick RL, Maeda N: Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-1821
29. Karathanasis SK, Ferris E, Haddad IA: DNA within the apolipoprotein A-I/C-III/A-IV-encoding gene cluster of certain patients with atherosclerosis. Proc Natl Acad Sci USA 1987; 84: 7198-7202
30. Funke H, von Eckardstein A, Pritchard PH et al: A frameshift mutation in the human apo A-I gene causes high density lipoprotein deficiency, partial lecithin:cholesterol acyl transferase deficiency and corneal opacities. J Clin Invest 1991; 87: 371-376
31. Lackner KJ, Dieplinger H, Nowicka G et al: High density lipoprotein deficiency with xanthomas: a defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest 1993; 92: 2262-2273
32. Romling R, von Eckardstein A, Funke H et al: A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb 1994; 14: 1915-1922
33. Ng DS, Leiter LA, Vezina C et al: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994; 93: 223-229
34. Quaid KA: Psychological and ethical considerations in screening for disease. Am J Cardiol 1993; 72: 64D-67D
35. Hegele RA, Breckenridge WC, Cox DW et al: Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations. Arterioscler Thromb 1991; 11: 1303-1309
36. Emi M, Hegele RA, Hopkins PN et al: Effects of three genetic loci in a family with multiple lipoprotein phenotypes. Arterioscler Thromb 1991; 11: 1303-1309
37. Hegele RA, Brunt JH, Connelly PW: A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995; 15: 89-95
38. Hegele RA, Brunt JH, Connelly PW: Genetic determinants of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol 1995; 15: 861-871
39. Cohen JC, Wang Z, Grundy SM et al: Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest 1994; 94: 2377-2384
40. Hegele RA, Little JA, Vezina C et al: Hepatic lipase deficiency: clinical, biochemical and molecular genetic characteristics. Arterioscler Thromb 1993; 13: 720-728
41. Zerba KE, Sing CF: The role of genome type-environment interaction and time in understanding the impact of genetic polymorphism on lipid metabolism. Curr Opin Lipidol 1993; 4: 152-162
42. Horgan J: From complexity to perplexity. Sci Am 1995; 272: 104-109